{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Head+and+Neck+Cancers+-+Throat&page=2", "query": { "condition": "Head and Neck Cancers - Throat", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Head+and+Neck+Cancers+-+Throat&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-25T22:13:08.240Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02292368", "title": "Neurological Effects of Acupuncture to Prevent Radiation-induced Xerostomia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "Questionnaires", "type": "BEHAVIORAL" }, { "name": "Acupuncture", "type": "PROCEDURE" }, { "name": "Electroencephalogram (EEG)", "type": "PROCEDURE" } ], "intervention_types": [ "BEHAVIORAL", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2014-11-10", "completion_date": "2022-08-30", "has_results": false, "last_update_posted_date": "2022-09-01", "last_synced_at": "2026-06-25T22:13:08.240Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02292368" }, { "nct_id": "NCT06457503", "title": "A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Nasopharyngeal Cancer Recurrent" ], "interventions": [ { "name": "Toripalimab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Coherus Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 100, "start_date": "2024-11-01", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-04-06", "last_synced_at": "2026-06-25T22:13:08.240Z", "location_count": 12, "location_summary": "Little Rock, Arkansas • Irvine, California • San Francisco, California + 9 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Irvine", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06457503" }, { "nct_id": "NCT00004097", "title": "Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced and/or Recurrent Head and Neck Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "fluorouracil", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1999-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-09-20", "last_synced_at": "2026-06-25T22:13:08.240Z", "location_count": 2, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004097" }, { "nct_id": "NCT00790569", "title": "Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Bladder Cancer", "Cervical Cancer", "Esophageal Cancer", "Gastric Cancer", "Head and Neck Cancer", "Kidney Cancer", "Leukemia", "Liver Cancer", "Lung Cancer", "Pancreatic Cancer", "Tobacco Use Disorder" ], "interventions": [ { "name": "nicotine", "type": "DRUG" }, { "name": "varenicline", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Butler Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 315, "start_date": "2008-09", "completion_date": "2012-10", "has_results": true, "last_update_posted_date": "2018-06-06", "last_synced_at": "2026-06-25T22:13:08.240Z", "location_count": 1, "location_summary": "Providence, Rhode Island", "locations": [ { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT00790569" }, { "nct_id": "NCT00004094", "title": "Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Advanced Cancer of the Mouth, Pharynx, or Larynx", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "hydroxyurea", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "15 Years to 80 Years" }, "enrollment_count": null, "start_date": "1999-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-01-06", "last_synced_at": "2026-06-25T22:13:08.240Z", "location_count": 4, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004094" }, { "nct_id": "NCT00036790", "title": "Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Chronic Myeloproliferative Disorders", "Colorectal Cancer", "Head and Neck Cancer", "Leukemia", "Lung Cancer", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic/Myeloproliferative Diseases", "Prostate Cancer", "Small Intestine Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "motexafin gadolinium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": null, "start_date": "2002-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2019-12-17", "last_synced_at": "2026-06-25T22:13:08.240Z", "location_count": 2, "location_summary": "Pittsburgh, Pennsylvania • Madison, Wisconsin", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00036790" }, { "nct_id": "NCT03429036", "title": "Biospecimen Procurement for Head and Neck Disorders", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hearing Disorder", "Oral Mucosal Disease", "Pharyngeal Neoplasm", "Head and Neck Neoplasms", "Laryngeal Disease" ], "interventions": [], "intervention_types": [], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "3 Years to 120 Years" }, "enrollment_count": 1000, "start_date": "2018-05-23", "completion_date": "2029-12-02", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-06-25T22:13:08.240Z", "location_count": 9, "location_summary": "Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03429036" }, { "nct_id": "NCT01552434", "title": "Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Neoplasm", "Castleman Disease", "Digestive System Carcinoma", "Erdheim-Chester Disease", "Lip and Oral Cavity Carcinoma", "Lymphangioleiomyomatosis", "Malignant Endocrine Neoplasm", "Malignant Female Reproductive System Neoplasm", "Malignant Male Reproductive System Neoplasm", "Malignant Neoplasm", "Malignant Respiratory Tract Neoplasm", "Malignant Thoracic Neoplasm", "Malignant Urinary System Neoplasm", "Mesothelial Neoplasm", "Metastatic Malignant Neoplasm", "Metastatic Urothelial Carcinoma", "Neurofibromatosis Type 2", "Recurrent Adult Soft Tissue Sarcoma", "Recurrent Breast Carcinoma", "Recurrent Childhood Soft Tissue Sarcoma", "Recurrent Digestive System Carcinoma", "Recurrent Female Reproductive System Carcinoma", "Recurrent Male Reproductive System Carcinoma", "Recurrent Malignant Neoplasm", "Recurrent Pharyngeal Carcinoma", "Recurrent Thyroid Gland Carcinoma", "Refractory Malignant Neoplasm", "Soft Tissue Neoplasm", "Stage III Breast Cancer AJCC v7", "Stage III Pharyngeal Cancer", "Stage IIIA Breast Cancer AJCC v7", "Stage IIIB Breast Cancer AJCC v7", "Stage IIIC Breast Cancer AJCC v7", "Stage IV Breast Cancer AJCC v6 and v7", "Stage IV Pharyngeal Cancer", "Stage IVA Pharyngeal Cancer", "Stage IVB Pharyngeal Cancer", "Stage IVC Pharyngeal Cancer", "Thyroid Gland Neoplasm" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Temsirolimus", "type": "DRUG" }, { "name": "Valproic Acid", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 154, "start_date": "2012-10-16", "completion_date": "2026-05-08", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-06-25T22:13:08.240Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01552434" }, { "nct_id": "NCT06636734", "title": "Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Human Papillomavirus-Related Neck Squamous Cell Carcinoma of Unknown Primary", "Metastatic Head and Neck Squamous Cell Carcinoma", "Metastatic Hypopharyngeal Squamous Cell Carcinoma", "Metastatic Laryngeal Squamous Cell Carcinoma", "Metastatic Nasopharyngeal Squamous Cell Carcinoma", "Metastatic Oral Cavity Squamous Cell Carcinoma", "Metastatic Oropharyngeal Squamous Cell Carcinoma", "Metastatic Paranasal Sinus Squamous Cell Carcinoma", "Recurrent Head and Neck Squamous Cell Carcinoma", "Recurrent Hypopharyngeal Squamous Cell Carcinoma", "Recurrent Laryngeal Squamous Cell Carcinoma", "Recurrent Nasopharyngeal Squamous Cell Carcinoma", "Recurrent Oral Cavity Squamous Cell Carcinoma", "Recurrent Oropharyngeal Squamous Cell Carcinoma", "Recurrent Paranasal Sinus Squamous Cell Carcinoma", "Stage IV Hypopharyngeal Carcinoma AJCC v8", "Stage IV Laryngeal Cancer AJCC v8", "Stage IV Lip and Oral Cavity Cancer AJCC v8", "Stage IV Nasopharyngeal Carcinoma AJCC v8", "Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IV Sinonasal Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Lovastatin", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2024-12-09", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-02-11", "last_synced_at": "2026-06-25T22:13:08.240Z", "location_count": 2, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06636734" }, { "nct_id": "NCT03267498", "title": "Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Nasopharyngeal Carcinoma" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Sue Yom", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2018-02-14", "completion_date": "2024-10-31", "has_results": true, "last_update_posted_date": "2026-01-12", "last_synced_at": "2026-06-25T22:13:08.240Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03267498" } ] }